Project: A low-cost intranasal vaccine that offers universal protection against pneumococcal infections.

PNEUMONAV will develop a novel intranasal prototype vaccine against pneumococcal infections, which will consist of Outer Membrane Vesicles (OMVs), displaying fragments of novel conserved protein antigens. These antigens will warrant universal protection against all pneumococcal serotypes and can be delivered via intranasal administration. If successful, this next-generation vaccine will be able to decrease the incidence of pneumococcal diseases worldwide.

Acronym	PNEUMONAV (Reference Number: 9285)
Duration	01/07/2015 - 01/02/2018
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 2

Project partner

Number	Name	Role	Country
20160	Drug Discovery Factory B.V.	Coordinator	Netherlands
20161	Abera Bioscience AB	Partner	Sweden
20162	Biotechpharma	Partner	Lithuania
20163	Medspray BV	Partner	Netherlands
20164	Vivo Science GmbH	Partner	Germany
20165	Radboud University Medical Center	Partner	Netherlands